#United Kingdom #Radiotherapy #Leo Cancer Care #Crawley #Marie®

Leo Cancer Care's Innovative Radiotherapy System Marie® Achieves CE Mark

In a groundbreaking announcement, Leo Cancer Care has confirmed that its leading system for upright radiotherapy, Marie®, has received the coveted CE marking. This significant milestone not only allows for the product's commercial deployment across Europe, but also represents a pivotal evolution in how radiotherapy is administered, tailoring treatment towards patient-centered care.

Historically, patients undergoing radiotherapy have had to lay flat and remain motionless, a requirement that has shaped everything from system design to clinical workflows. However, Marie® challenges this traditional approach by allowing patients to receive treatment while in a vertical position. Stephen Towe, CEO of Leo Cancer Care, stated, "This system is more than just a regulatory step; it's transforming upright radiotherapy into a clinical reality for European patients." With this user-centric design, Marie® emphasizes a new paradigm in cancer care, providing a more natural treatment experience and streamlining operational efficiency in cancer care facilities.

A New Paradigm of Patient Experience

By facilitating treatment in an upright posture, Marie® aims to redefine the patient experience during radiotherapy. Not only does this enhance comfort, but it also opens new avenues for treatment administration, accommodating advanced techniques like arc therapy and online adaptive radiotherapy. This innovation could significantly improve access to treatment for institutions unable to accommodate traditional particle therapy setups.

Marie® is built on the principles of adaptability and patient-centered design, serving as a ready-made platform for the next generation of radiotherapy solutions. It stands out as the first of its kind to offer a vertical patient positioning system that integrates seamlessly with multiple beam types and hadrontherapy methods, making it an essential advancement in modern oncology.

Ensuring Clinical Excellence with CE Marking

Years of meticulous research, engineering, and collaboration with key stakeholders in the radio-oncology ecosystem culminated in Marie® achieving CE marking, affirming that it meets the stringent European standards for safety, performance, and clinical availability. One of the project's prestigious partners is the Centre Léon Bérard, which is dedicated to cancer research and treatment. With CE approval in hand, the partnership will now expand to include anatomical imaging and vertical positioning, leveraging Marie's state-of-the-art vertical CT capabilities.

A Catalyst for Future Advances in Hadrontherapy

For Leo Cancer Care, this achievement is just the beginning. The European facilities are set to commence operations with the Centro Nazionale di Adroterapia Oncologica (CNAO) in Italy, aiming to start treatments by the end of this year. Dr. Sandro Rossi, the medical director at CNAO, remarked on the significance of collaborating with Leo Cancer Care: "The integration of LCC's vertical positioning system into our clinical workflow marks a profound turning point for CNAO. Coupled with our multi-ion horizontal beam, we are pioneering a new advanced method aimed at optimizing treatment precision and fundamentally enhancing our clinical capacity. This synergy pushes us further in our commitment to provide personalized, accessible, and innovative oncology solutions. We look forward to closely collaborating with Leo Cancer Care on system installation, commissioning, and administering the first patient treatments."

In summary, Leo Cancer Care is actively working with leading cancer centers throughout Europe to implement upright radiotherapy into clinical practice, thereby accelerating the uptake of a solution developed with an eye towards treatment precision and patient experience. With this innovative approach, the landscape of cancer treatment is set to change for the better.